Similarly, frequencies of CLL cells expressing CD23 were decreased in both therapy groups, although we note that a small number of IBR treated patients showed minimal changes in frequencies of CD23+ CLL cells (Figure 1D). The gene discussed is FCER2; the disease is B-cell chronic lymphocytic leukemia.